Moleculin Biotech, Inc. - 8-K Filing
Moleculin Biotech receives decision to grant South Korean patent for liposomal Annamycin reconstitution method. (Items: 7.01 Regulation FD Disclosure On November 18, 2026, Moleculin Biotech, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $MBRX
Read the full article at SEC EDGAR
Part of the story Edesa Biotech, Inc. - 8-K Filing (3 articles)